title: Gadodiamide in renal transplant patients: effects on renal function and usefulness as a glomerular filtration rate marker.
abstract: Gadodiamide at a dose of 0.1 mmol/kg was administered intravenously to 10 renal transplanted patients with stable, impaired, or slowly deteriorating renal function (serum creatinine 194-362 mumol/l). The patients were referred for contrast medium enhanced magnetic resonance imaging to rule out possible graft circulation abnormalities. The excretion of gadodiamide in urine was prolonged as compared with healthy controls. After 120 h 92% of the injected dose was excreted in urine and only 0.4% in faeces. The plasma clearance of gadodiamide was 28.6 +/- (SD) 5.5 ml/min (n = 10), and the renal clearance (0-72 h) was 26.3 ml/min. The renal clearance of 125I-iothalamate for the same time period was 27.9 +/- 5.3 ml/min. Thus, gadodiamide is eliminated by glomerular filtration also in renal transplant patients with moderately to severe impaired renal function, and gadodiamide clearance may serve as an alternative marker for the determination of the glomerular filtration rate. Serum values of creatinine and beta(2)-microglobulin and creatinine clearance were unchanged by gadodiamide and neither was the urinary enzyme excretion significantly changed. These results suggest that the renal tolerance to gadodiamide is good also in renal transplant patients with impaired renal function.
authors.affiliation: Medical Department B, Rikshospitalet, Oslo, Norway.
authors.forename: K J
authors.initials: KJ
authors.lastname: Berg
authors.forename: B
authors.initials: B
authors.lastname: Lundby
authors.forename: V
authors.initials: V
authors.lastname: Reinton
authors.forename: K P
authors.initials: KP
authors.lastname: Nordal
authors.forename: K
authors.initials: K
authors.lastname: Rootwelt
authors.forename: H J
authors.initials: HJ
authors.lastname: Smith
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers; D003287:Contrast Media; D003404:Creatinine / Q000097:blood; D005260:Female; D005682:Gadolinium; D019786:Gadolinium DTPA; D005919:Glomerular Filtration Rate / Q000502:physiology*; D006207:Half-Life; D006801:Humans; D007275:Injections, Intravenous; D007457:Iodine Radioisotopes / Q000493:pharmacokinetics; D007483:Iothalamic Acid / Q000493:pharmacokinetics; D007668:Kidney / Q000187:drug effects / Q000502:physiology*; D007674:Kidney Diseases / Q000378:metabolism* / Q000503:physiopathology; D007678:Kidney Glomerulus / Q000378:metabolism; D016030:Kidney Transplantation / Q000502:physiology*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds / Q000493:pharmacokinetics* / Q000494:pharmacology; D004369:Pentetic Acid / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology; D001613:beta 2-Microglobulin / Q000378:metabolism
chemical_list: D015415:Biomarkers; D003287:Contrast Media; D007457:Iodine Radioisotopes; D009942:Organometallic Compounds; D001613:beta 2-Microglobulin; D007483:Iothalamic Acid; D004369:Pentetic Acid; C064925:gadodiamide; D005682:Gadolinium; D003404:Creatinine; D019786:Gadolinium DTPA